DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
CIPARGAMIN
2
Small molecule
Investigational
Unknown
Unknown
Malaria; Malaria, Falciparum
P-type ATPase inhibitor
CIPARGAMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Z7Q4FWA04P
Molecule Type:
Small molecule
Molecular Formula:
C19H14Cl2FN3O
Molecular Weight:
390.25
AlogP:
4.34
PSA:
56.92
HBD:
3.0
HBA:
#RotB:
0.0
Source:
INO-1001
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
INO-1001
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CENERIMOD
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Liver Diseases; Lupus Erythematosus, Systemic
Sphingosine 1-phosphate receptor Edg-1 modulator
CENERIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
Y333RS1786
Molecule Type:
Small molecule
Molecular Formula:
C25H31N3O5
Molecular Weight:
453.54
AlogP:
4.07
PSA:
110.73
HBD:
2.0
HBA:
#RotB:
9.0
Source:
TIRABRUTINIB
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Chronic Urticaria; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms; Sjogren's Syndrome
Tyrosine-protein kinase BTK inhibitor
TIRABRUTINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
LXG44NDL2T
Molecule Type:
Small molecule
Molecular Formula:
C25H22N6O3
Molecular Weight:
454.49
AlogP:
2.75
PSA:
108.27
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ILACIRNON
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerulosclerosis, Focal Segmental
C-C chemokine receptor type 2 antagonist
ILACIRNON
×
Maximum Phase:
2
First Approval:
None
UNII:
380F68J5PH
Molecule Type:
Small molecule
Molecular Formula:
C20H13ClF3N5O3S
Molecular Weight:
495.87
AlogP:
4.37
PSA:
117.7
HBD:
2.0
HBA:
#RotB:
5.0
Source:
PEXACERFONT
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Anxiety Disorders; Irritable Bowel Syndrome
Corticotropin releasing factor receptor 1 antagonist
PEXACERFONT
×
Maximum Phase:
2
First Approval:
None
UNII:
LF1VBG4ZUK
Molecule Type:
Small molecule
Molecular Formula:
C18H24N6O
Molecular Weight:
340.43
AlogP:
3.33
PSA:
77.23
HBD:
1.0
HBA:
#RotB:
5.0
Source:
EXEPORFINIUM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
EXEPORFINIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
R41ECT47G6
Molecule Type:
Small molecule
Molecular Formula:
C44H50N6O2+2
Molecular Weight:
694.92
AlogP:
8.94
PSA:
75.82
HBD:
2.0
HBA:
#RotB:
12.0
Source:
CC-11050
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CC-11050
×
Maximum Phase:
2
First Approval:
None
UNII:
1Z08G7438A
Molecule Type:
Small molecule
Molecular Formula:
C24H28N2O6S
Molecular Weight:
472.56
AlogP:
3.18
PSA:
102.01
HBD:
1.0
HBA:
#RotB:
9.0
Source:
BLX-028914
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BLX-028914
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATEVIRDINE MESYLATE
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
ATEVIRDINE MESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
A948D8673W
Molecule Type:
Small molecule
Molecular Formula:
C21H25N5O2
Molecular Weight:
379.46
AlogP:
2.97
PSA:
73.49
HBD:
2.0
HBA:
#RotB:
5.0
Source:
TENOFOVIR EXALIDEX
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Communicable Diseases
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
TENOFOVIR EXALIDEX
×
Maximum Phase:
2
First Approval:
None
UNII:
K7J545MEMA
Molecule Type:
Small molecule
Molecular Formula:
C28H52N5O5P
Molecular Weight:
569.73
AlogP:
6.86
PSA:
134.61
HBD:
2.0
HBA:
#RotB:
25.0
Source:
GSK239512
2
Small molecule
Investigational
Unknown
Unknown
Cognitive Dysfunction; Dementia; Multiple Sclerosis; Alzheimer Disease; Multiple Sclerosis, Relapsing-Remitting; Schizophrenia
Histamine H3 receptor antagonist
GSK239512
×
Maximum Phase:
2
First Approval:
None
UNII:
4I7U5C459M
Molecule Type:
Small molecule
Molecular Formula:
C23H27N3O2
Molecular Weight:
377.49
AlogP:
3.95
PSA:
45.67
HBD:
0.0
HBA:
#RotB:
4.0
Source:
LADARIXIN
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Pemphigoid, Bullous; Diabetes Mellitus, Type 1
Interleukin-8 receptor A modulator
LADARIXIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DEH7Q6472O
Molecule Type:
Small molecule
Molecular Formula:
C11H12F3NO6S2
Molecular Weight:
375.35
AlogP:
1.09
PSA:
106.61
HBD:
1.0
HBA:
#RotB:
5.0
Source:
DU 125530
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder
Serotonin 1a (5-HT1a) receptor antagonist
DU 125530
×
Maximum Phase:
2
First Approval:
None
UNII:
ZB05V621UD
Molecule Type:
Small molecule
Molecular Formula:
C23H26ClN3O5S
Molecular Weight:
492.0
AlogP:
2.86
PSA:
79.39
HBD:
0.0
HBA:
#RotB:
6.0
Source:
ISTAROXIME
2
Small molecule
Investigational
Unknown
Unknown
Heart Failure; Shock
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
ISTAROXIME
×
Maximum Phase:
2
First Approval:
None
UNII:
W8I9H2TPPL
Molecule Type:
Small molecule
Molecular Formula:
C21H32N2O3
Molecular Weight:
360.5
AlogP:
3.11
PSA:
81.75
HBD:
1.0
HBA:
#RotB:
3.0
Source:
CALCIMYCIN
2
Small molecule
Investigational
Unknown
Unknown
Infertility; Infertility, Male
Unknown
CALCIMYCIN
×
Maximum Phase:
2
First Approval:
None
UNII:
37H9VM9WZL
Molecule Type:
Small molecule
Molecular Formula:
C29H37N3O6
Molecular Weight:
523.63
AlogP:
5.53
PSA:
126.68
HBD:
3.0
HBA:
#RotB:
7.0
Source:
PERILLYL ALCOHOL
2
Small molecule
Investigational
Unknown
Unknown
Glioblastoma; Lymphoma; Breast Neoplasms; Keratosis, Actinic; Meningioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
PERILLYL ALCOHOL
×
Maximum Phase:
2
First Approval:
None
UNII:
319R5C7293
Molecule Type:
Small molecule
Molecular Formula:
C10H16O
Molecular Weight:
152.24
AlogP:
2.28
PSA:
20.23
HBD:
1.0
HBA:
#RotB:
2.0
Source:
ISOPENTYL 2-CYANOACRYLATE
2
Small molecule
Investigational
Unknown
Unknown
Infertility; Hypospadias
Unknown
ISOPENTYL 2-CYANOACRYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
3977IRA64J
Molecule Type:
Small molecule
Molecular Formula:
C9H13NO2
Molecular Weight:
167.21
AlogP:
1.66
PSA:
50.09
HBD:
0.0
HBA:
#RotB:
4.0
Source:
IMARIKIREN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Renin inhibitor
IMARIKIREN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1NE31CW68S
Molecule Type:
Small molecule
Molecular Formula:
C27H42ClN5O4
Molecular Weight:
536.12
AlogP:
2.4
PSA:
88.93
HBD:
1.0
HBA:
#RotB:
10.0
Source:
PD-0299685
2
Small molecule
Investigational
Unknown
Unknown
Cystitis, Interstitial; Hot Flashes
Unknown
PD-0299685
×
Maximum Phase:
2
First Approval:
None
UNII:
61SA6645RL
Molecule Type:
Small molecule
Molecular Formula:
C10H21NO2
Molecular Weight:
187.28
AlogP:
1.86
PSA:
63.32
HBD:
2.0
HBA:
#RotB:
7.0
Source:
MBX-2982
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus; Diabetes Mellitus, Type 1
Glucose-dependent insulinotropic receptor agonist
MBX-2982
×
Maximum Phase:
2
First Approval:
None
UNII:
B5TRY67L51
Molecule Type:
Small molecule
Molecular Formula:
C22H24N8OS
Molecular Weight:
448.56
AlogP:
3.43
PSA:
94.74
HBD:
0.0
HBA:
#RotB:
7.0
Source:
LEMUTEPORFIN
2
Small molecule
Investigational
Unknown
Unknown
Acne Vulgaris; Prostatic Hyperplasia
Unknown
LEMUTEPORFIN
×
Maximum Phase:
2
First Approval:
None
UNII:
EZ109VJ012
Molecule Type:
Small molecule
Molecular Formula:
C45H50N4O9
Molecular Weight:
790.91
AlogP:
6.84
PSA:
182.79
HBD:
3.0
HBA:
#RotB:
13.0
Source:
XL-999
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Multiple Myeloma; Ovarian Neoplasms
Fibroblast growth factor receptor inhibitor
XL-999
×
Maximum Phase:
2
First Approval:
None
UNII:
6I7PLF6N8L
Molecule Type:
Small molecule
Molecular Formula:
C26H28FN5O
Molecular Weight:
445.54
AlogP:
4.66
PSA:
73.05
HBD:
3.0
HBA:
#RotB:
5.0
Source:
ATICAPRANT
2
Small molecule
Investigational
Unknown
Unknown
Anxiety; Depressive Disorder, Treatment-Resistant; Tobacco Use Disorder; Depressive Disorder, Major
Kappa opioid receptor antagonist
ATICAPRANT
×
Maximum Phase:
2
First Approval:
None
UNII:
DE4G8X55F5
Molecule Type:
Small molecule
Molecular Formula:
C26H27FN2O2
Molecular Weight:
418.51
AlogP:
5.67
PSA:
55.56
HBD:
1.0
HBA:
#RotB:
6.0
Source:
VACTOSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Desmoid Tumors; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Myeloproliferative Disorders; Stomach Neoplasms; Urinary Bladder Neoplasms
TGF-beta receptor type I inhibitor
VACTOSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
6T4O391P5Y
Molecule Type:
Small molecule
Molecular Formula:
C22H18FN7
Molecular Weight:
399.43
AlogP:
4.24
PSA:
83.79
HBD:
2.0
HBA:
#RotB:
5.0
Source:
NCX-4016
2
Small molecule
Investigational
Unknown
Unknown
Intermittent Claudication
Unknown
NCX-4016
×
Maximum Phase:
2
First Approval:
None
UNII:
EH04H13L6B
Molecule Type:
Small molecule
Molecular Formula:
C16H13NO7
Molecular Weight:
331.28
AlogP:
2.54
PSA:
104.97
HBD:
0.0
HBA:
#RotB:
6.0
Source:
OT-551
2
Small molecule
Investigational
Unknown
Unknown
Geographic Atrophy; Macular Degeneration
Antiinflammatory, antioxidant
OT-551
×
Maximum Phase:
2
First Approval:
None
UNII:
DZ02S3A31N
Molecule Type:
Small molecule
Molecular Formula:
C13H23NO3
Molecular Weight:
241.33
AlogP:
2.35
PSA:
49.77
HBD:
1.0
HBA:
#RotB:
2.0
Source:
KETOPROFEN SODIUM
2
Small molecule
Investigational
Unknown
Unknown
Muscular Diseases
Unknown
KETOPROFEN SODIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
5R10M39KS7
Molecule Type:
Small molecule
Molecular Formula:
C16H13NaO3
Molecular Weight:
276.27
AlogP:
3.11
PSA:
54.37
HBD:
1.0
HBA:
#RotB:
4.0
Source:
(+)-SECOISOLARICIRESINOL
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
(+)-SECOISOLARICIRESINOL
×
Maximum Phase:
2
First Approval:
None
UNII:
1UK6IPG91I
Molecule Type:
Small molecule
Molecular Formula:
C20H26O6
Molecular Weight:
362.42
AlogP:
2.12
PSA:
99.38
HBD:
4.0
HBA:
#RotB:
9.0
Source:
RITANSERIN
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
RITANSERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
145TFV465S
Molecule Type:
Small molecule
Molecular Formula:
C27H25F2N3OS
Molecular Weight:
477.58
AlogP:
5.48
PSA:
37.61
HBD:
0.0
HBA:
#RotB:
5.0
Source:
INCB-047986
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Hodgkin Disease; Myelodysplastic Syndromes; Arthritis, Rheumatoid
Tyrosine-protein kinase JAK1 inhibitor
INCB-047986
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TETRAHYDROPALMATINE
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
TETRAHYDROPALMATINE
×
Maximum Phase:
2
First Approval:
None
UNII:
3X69CO5I79
Molecule Type:
Small molecule
Molecular Formula:
C21H25NO4
Molecular Weight:
355.43
AlogP:
3.38
PSA:
40.16
HBD:
0.0
HBA:
#RotB:
4.0
Source:
FIALURIDINE
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis B, Chronic; Herpes Simplex
Unknown
FIALURIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
53T7IN77LC
Molecule Type:
Small molecule
Molecular Formula:
C9H10FIN2O5
Molecular Weight:
372.09
AlogP:
-1.27
PSA:
104.55
HBD:
3.0
HBA:
#RotB:
2.0
Source:
LAPACHONE
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma; Neoplasms
Unknown
LAPACHONE
×
Maximum Phase:
2
First Approval:
None
UNII:
6N4FA2QQ6A
Molecule Type:
Small molecule
Molecular Formula:
C15H14O3
Molecular Weight:
242.27
AlogP:
2.75
PSA:
43.37
HBD:
0.0
HBA:
#RotB:
0.0
Source:
MIVAVOTINIB CITRATE
2
Small molecule
Investigational
Unknown
Unknown
Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Neoplasms; Lymphoma, Large B-Cell, Diffuse
Tyrosine-protein kinase SYK inhibitor
MIVAVOTINIB CITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
6ZJ8V3Q0H1
Molecule Type:
Small molecule
Molecular Formula:
C23H29FN6O8
Molecular Weight:
536.52
AlogP:
1.55
PSA:
97.86
HBD:
3.0
HBA:
#RotB:
3.0
Source:
1
2
…
95
96
97
98
99
100
101
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA